CompletedNot Applicable

Prediction of Multidrug-resistant Bacterial Infection in Patients with Cirrhosis

Argentina1,774 participantsStarted 2022-11-16

Plain-language summary

The aim of this study is to identify predictive factors of infections caused by multidrug-resistant organisms in patients with cirrhosis and to develop and validate (internally and externally) a predictive model that might be useful to use in clinical settings to stratify the risk and lead clinical decision-making strategies.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. age ≥ 18 years
✓. with cirrhosis
✓. who presented their first confirmed diagnosis of bacterial infection during the study period, either at admission or during hospitalization

Exclusion criteria

✕. hepatocellular carcinoma beyond the Milan criteria;
✕. extrahepatic malignancy;
✕. severe extrahepatic disease (congestive heart failure \[New York Heart Association stage3\], chronic obstructive pulmonary disease \[Global Initiative for Chronic Obstructive Lung Disease stage 3\]; chronic kidney disease requiring renal replacement therapy \[RRT\]);
✕. previous solid organ transplantation;
✕. human immunodeficiency viral infection;
✕. use of immunosuppressive drugs other than corticosteroids for the treatment of severe acute alcoholic hepatitis; and
✕. inability to provide written informed consent.

What they're measuring

Infection caused by multidrug-resistan organism

Timeframe: 24-48 hours (it is a cross sectional study)

Trial details

NCT IDNCT05641025

SponsorHospital Italiano de Buenos Aires

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-12-30

View on ClinicalTrials.gov More Drug Resistance, Multiple trials